CA3086598A1 - Optimized host/vector system for producing protective mono- and multivalent subunit vaccines on the basis of the yeast kluyveromyces lactis - Google Patents
Optimized host/vector system for producing protective mono- and multivalent subunit vaccines on the basis of the yeast kluyveromyces lactis Download PDFInfo
- Publication number
- CA3086598A1 CA3086598A1 CA3086598A CA3086598A CA3086598A1 CA 3086598 A1 CA3086598 A1 CA 3086598A1 CA 3086598 A CA3086598 A CA 3086598A CA 3086598 A CA3086598 A CA 3086598A CA 3086598 A1 CA3086598 A1 CA 3086598A1
- Authority
- CA
- Canada
- Prior art keywords
- lactis
- lactis strain
- strain
- gene
- locus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Botany (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102017012109.5A DE102017012109A1 (de) | 2017-12-27 | 2017-12-27 | Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis |
| DE102017012109.5 | 2017-12-27 | ||
| PCT/DE2018/000379 WO2019129321A2 (de) | 2017-12-27 | 2018-12-19 | Optimiertes wirts-/vektorsystem zur erzeugung protektiver mono- und multivalenter subunit-vakzine auf basis der hefe kluyveromyces lactis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3086598A1 true CA3086598A1 (en) | 2019-07-04 |
Family
ID=65817691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3086598A Pending CA3086598A1 (en) | 2017-12-27 | 2018-12-19 | Optimized host/vector system for producing protective mono- and multivalent subunit vaccines on the basis of the yeast kluyveromyces lactis |
Country Status (18)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4001417A1 (en) * | 2020-11-13 | 2022-05-25 | serYmun Yeast GmbH | Yeast platform for the production of vaccines |
| WO2026119376A1 (de) | 2024-12-03 | 2026-06-11 | Verovaccines Gmbh | Sedimentations-stabilisierte formulierungen für hefe-basierte vakzine |
| CN119391747B (zh) * | 2024-12-12 | 2025-11-18 | 华中农业大学 | 一种利用马克斯克鲁维酵母制备禽传染性法氏囊病vp2纳米颗粒口服疫苗的方法及应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| AU2002225681A1 (en) | 2000-11-15 | 2002-05-27 | Globe Immune, Inc. | Yeast-dentritic cell vaccines and uses thereof |
| JP4914990B2 (ja) | 2002-12-16 | 2012-04-11 | グローブイミューン，インコーポレイテッド | 動物を癌から守るための治療用組成物 |
| KR20070068460A (ko) | 2004-10-18 | 2007-06-29 | 글로브이뮨 | 만성 ｃ형 간염에 대한 효모계 치료 |
| CA2638815A1 (en) | 2006-02-02 | 2007-08-16 | Globeimmune, Inc. | Yeast-based vaccine for inducing an immune response |
| DE102008057451A1 (de) | 2008-11-14 | 2010-05-20 | Martin-Luther-Universität Halle-Wittenberg | Verfahren zur oralen Vakzinierung mittels rekombinanter Hefen |
| ES2660597T3 (es) | 2009-04-17 | 2018-03-23 | Globeimmune, Inc. | Composiciones inmunoterápicas de combinación contra el cáncer y métodos |
| DE102011121069A1 (de) | 2011-12-13 | 2013-06-13 | Martin-Luther-Universität Halle-Wittenberg | Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene |
-
2017
- 2017-12-27 DE DE102017012109.5A patent/DE102017012109A1/de not_active Ceased
-
2018
- 2018-12-19 DK DK18857443.8T patent/DK3732293T3/da active
- 2018-12-19 BR BR112020013245-4A patent/BR112020013245A2/pt unknown
- 2018-12-19 MX MX2020006846A patent/MX2020006846A/es unknown
- 2018-12-19 HU HUE18857443A patent/HUE068358T2/hu unknown
- 2018-12-19 CN CN201880083894.1A patent/CN111801422B/zh active Active
- 2018-12-19 CA CA3086598A patent/CA3086598A1/en active Pending
- 2018-12-19 ES ES18857443T patent/ES2990197T3/es active Active
- 2018-12-19 PT PT188574438T patent/PT3732293T/pt unknown
- 2018-12-19 JP JP2020555291A patent/JP7782951B2/ja active Active
- 2018-12-19 HR HRP20241297TT patent/HRP20241297T1/hr unknown
- 2018-12-19 US US16/958,170 patent/US11905517B2/en active Active
- 2018-12-19 EA EA202091435A patent/EA202091435A1/ru unknown
- 2018-12-19 KR KR1020207021778A patent/KR102704217B1/ko active Active
- 2018-12-19 PL PL18857443.8T patent/PL3732293T3/pl unknown
- 2018-12-19 WO PCT/DE2018/000379 patent/WO2019129321A2/de not_active Ceased
- 2018-12-19 EP EP18857443.8A patent/EP3732293B1/de active Active
- 2018-12-19 DE DE112018006647.9T patent/DE112018006647A5/de not_active Withdrawn
-
2020
- 2020-06-12 ZA ZA2020/03553A patent/ZA202003553B/en unknown
-
2023
- 2023-08-16 JP JP2023132434A patent/JP2023166412A/ja active Pending
- 2023-10-05 US US18/481,345 patent/US12473562B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3732293A2 (de) | 2020-11-04 |
| CN111801422A (zh) | 2020-10-20 |
| PT3732293T (pt) | 2024-10-09 |
| HUE068358T2 (hu) | 2024-12-28 |
| WO2019129321A3 (de) | 2019-09-12 |
| JP7782951B2 (ja) | 2025-12-09 |
| KR102704217B1 (ko) | 2024-09-09 |
| CN111801422B (zh) | 2024-06-14 |
| WO2019129321A2 (de) | 2019-07-04 |
| ZA202003553B (en) | 2021-06-30 |
| EP3732293B1 (de) | 2024-07-03 |
| HRP20241297T1 (hr) | 2024-12-20 |
| MX2020006846A (es) | 2020-11-06 |
| ES2990197T3 (es) | 2024-11-29 |
| DE102017012109A1 (de) | 2019-06-27 |
| PL3732293T3 (pl) | 2024-11-18 |
| DK3732293T3 (da) | 2024-09-23 |
| US20240102031A1 (en) | 2024-03-28 |
| KR20200104367A (ko) | 2020-09-03 |
| US12473562B2 (en) | 2025-11-18 |
| US20210230612A1 (en) | 2021-07-29 |
| EA202091435A1 (ru) | 2020-08-28 |
| US11905517B2 (en) | 2024-02-20 |
| BR112020013245A2 (pt) | 2020-12-01 |
| JP2021508496A (ja) | 2021-03-11 |
| JP2023166412A (ja) | 2023-11-21 |
| DE112018006647A5 (de) | 2020-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12473562B2 (en) | Optimized host/vector system for producing protective mono-and multivalent subunit vaccines on the basis of the yeast Kluyveromyces lactis | |
| JP7113924B2 (ja) | 組み換え改変ワクシニアウイルスアンカラ（ｍｖａ）フィロウイルスワクチン | |
| Arnold et al. | Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit | |
| JP6990814B2 (ja) | アヒル腸炎ウイルス及びその使用 | |
| CN108368488B (zh) | 鸭肠炎病毒及其用途 | |
| JP5675789B2 (ja) | 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型 | |
| RU2630620C2 (ru) | Вакцинация с помощью рекомбинантных дрожжей с формированием защитного гуморального иммунного ответа против определенных антигенов | |
| CN112458033A (zh) | 减毒鼠伤寒沙门菌及其构建方法与应用 | |
| Mahmood et al. | DNA vaccination with VP2 gene of very virulent infectious bursal disease virus (vvIBDV) delivered by transgenic E. coli DH5α given orally confers protective immune responses in chickens | |
| ES2669018T3 (es) | Procedimiento para la vacunación por vía oral/mucosa por medio de levaduras recombinantes | |
| KR20260066090A (ko) | 신규한 dev 벡터 | |
| CN121752290A (zh) | Dev作载体的禽流感h9疫苗 | |
| Mekalanos | Live attenuated vaccine vectors | |
| Afshar et al. | Comprehensive Review of Fowl and Duck Adenovirus Vaccines Development: Innovations, Challenges, and Future Directions. | |
| Loessner et al. | Employing live microbes for vaccine delivery | |
| EA045050B1 (ru) | Оптимизированная система вектор-хозяин для получения защитной моно- и поливалентной субъединичной вакцины на основе дрожжей kluyveromyces lactis | |
| WO2025044920A2 (en) | New dev vectors for avian vaccines | |
| De Ganzó et al. | Virus-Like Particles: Applications in Reverse Vaccinology | |
| CN118813706A (zh) | 表达传染性法氏囊病病毒vp2基因的重组新城疫病毒疫苗株及其构建方法与应用 | |
| WO2005009372A2 (en) | Marek’s disease virus vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220607 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240906 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241210 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241210 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241210 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241219 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250217 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250528 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250528 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20251028 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251031 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251208 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251208 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251208 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251211 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251211 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260416 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260416 |